The Europe Humanized Mouse and Rat Model Market was valued at $66.9 Million in 2025 and projected to reach to $101.4 Million by 2030, representing a compound annual growth rate of 8.7%. Europe's humanized mouse and rat model market is positioned for sustained expansion through 2030, driven by increasing R&D investments from pharmaceutical and biotechnology companies seeking advanced preclinical testing solutions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's humanized mouse and rat model market is valued at $66.9 million in 2025, with a robust CAGR of 8.7%, significantly outpacing the global growth rate of 8.2% and reaching $101.4 million by 2030.
Germany dominates Europe's market with $43 million in market size, reflecting its position as a leading hub for pharmaceutical research and development with world-class preclinical research infrastructure.
Europe's stringent regulatory frameworks and advanced research infrastructure create a favorable environment for humanized model adoption, supporting the transition from traditional to advanced in vivo disease modeling approaches.
Europe's robust pharmaceutical and biotechnology sectors are increasingly investing in humanized mouse and rat models to accelerate drug discovery, reduce development timelines, and improve clinical trial success rates.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.2% from 2025 to 2030 |
| Largest Segment | HUMANIZED MOUSE MODELS (Type) |
| Market Size Base Year (Billions) | ~USD 0.28 (2025) |
| Revenue Forecast (Billions) | ~USD 0.41 (2030) |
| Segments Covered | Type, End User, Application |
3 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 1.7 | 1.7 | 1.8 | 1.9 | 2 | 2.1 | 2.2 | 2.3 | 5 |
| CROS AND CDMOS | 2.8 | 2.9 | 3.2 | 3.5 | 3.8 | 4.1 | 4.5 | 4.9 | 8.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 6.1 | 6.4 | 6.8 | 7.4 | 7.9 | 8.5 | 9 | 9.7 | 7.2 |
| TOTAL | 10.6 | 11 | 11.8 | 12.7 | 13.7 | 14.7 | 15.7 | 16.8 | 7.3 |
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 11.3 | 11.5 | 12.2 | 13 | 13.8 | 14.6 | 15.4 | 16.2 | 5.8 |
| CROS AND CDMOS | 19.2 | 20.4 | 22.4 | 24.8 | 27.2 | 29.8 | 32.6 | 35.7 | 9.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 42.3 | 44.3 | 47.8 | 52 | 56.3 | 60.7 | 65.5 | 70.6 | 8.1 |
| TOTAL | 72.8 | 76.2 | 82.3 | 89.8 | 97.3 | 105.1 | 113.5 | 122.5 | 8.3 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support), |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software, |
| ONCODESIGN SERVICES | France | Public Company | Precision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers, |
Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.
Inotiv is a public company founded in 1974 in the United States with 1,996 employees.
Genoway is a public company founded in 1999 in France with 157 employees.
JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.
Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.
Oncodesign Services is a public company founded in 1995 in France.
| Country | 2025 size (native) |
|---|---|
| Germany | USD 43 Million |
| UK | USD 27.3 Million |
| France | USD 18.6 Million |
| Italy | USD 5.9 Million |
| Spain | USD 4.9 Million |
| Rest Of Europe | USD 13.9 Million |
Europe's humanized mouse and rat model market was valued at $66.9 million in 2025 and is expected to reach $101.4 million by 2030.
Europe's market is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2030, exceeding the global average.
Europe's growth is driven by strong pharmaceutical R&D investments, advanced regulatory frameworks, collaborative research networks, and emphasis on translational medicine and personalized healthcare.
Europe's pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic research institutions are the primary drivers of humanized model adoption.
Humanized mouse and rat models in Europe are accelerating drug development timelines, improving human drug response prediction, and reducing preclinical development costs for pharmaceutical companies.
The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.
Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.
Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The breakdown of the primary respondents is given below.
To know about the assumptions considered for the study, download the pdf brochure
Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.
A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.
To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report